- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07706465
A Two-Way Path to Health: Environmental Influences on Skeletal Muscle Endocrine Function (COMPASS)
A Two-Way Path to Health: Exploring Whether Environmental Factors Influence Skeletal Muscle Endocrine Function and Modulate Physical Activity-Induced Adaptations in Middle-Aged Women
Given the well-established anti-inflammatory and health-promoting effects of physical activity as a non-pharmacological intervention, an important question remains whether different types of exercise differ in their ability to reduce the body burden of per- and polyfluoroalkyl substances (PFAS) and whether PFAS exposure modifies exercise-induced adaptive responses. The investigators hypothesize that the coexistence of physical inactivity, overweight/obesity, reduced muscle mass, and consequently lower concentrations of myokines/exerkines contributes to impaired cardiovascular function, reduced exercise capacity, and a greater PFAS body burden. Collectively, these factors may adversely affect work ability, reduce occupational participation, and discourage continued employment among middle-aged women. In the context of unfavorable demographic trends, such consequences may represent a significant economic burden for society.
The primary objective of this project is to determine whether baseline PFAS concentrations are associated with the health status of women entering the study and to characterize circulating profiles of myokines/exerkines and arginine metabolites. A secondary objective is to compare the effects of different exercise programs on PFAS concentrations and their potential elimination from the body. In addition, we will investigate whether a history of cancer treatment, despite increasingly favorable clinical outcomes, is associated with long-term alterations in skeletal muscle endocrine function, myokine and exerkine release, and PFAS body burden.
The study will include perimenopausal women. Participants will be allocated to one of two supervised exercise programs: high-intensity circuit training (HICT) or interval walking training (IWT). Both interventions will last six months and will be performed two times per week (with possible additional unit performed at home). This period will be followed by six months of unsupervised maintenance training. Two additional groups will be included: a control group maintaining their usual lifestyle and a group of women who have completed cancer treatment. Participants in the oncology group will be instructed to maintain a daily physical activity level of approximately 7,000-10,000 steps.
Assessments will be performed at baseline, immediately after the intervention, and six months after its completion. Circulating concentrations of selected myokines, exerkines, arginine metabolites, and 18 PFAS compounds will be measured in blood, while PFAS concentrations will also be determined in urine samples. Cardiorespiratory fitness, body composition assessed by dual-energy X-ray absorptiometry (DXA), dietary habits, quality of life, and health literacy will also be evaluated.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
To date, PFAS exposure has been linked to disturbances in lipid and cholesterol metabolism, oxidative stress, and endocrine dysfunction, including alterations in thyroid and steroid hormone regulation. However, there is a lack of data regarding the effects of PFAS-chemicals widely used in numerous industrial and consumer applications and ubiquitous in the environment-on exercise-induced adaptive responses.
Over the past two decades, research has demonstrated the critical role of specific proteins released by skeletal muscle (myokines) and other organs, including the brain, heart, and liver (collectively referred to as exerkines), in mediating physiological adaptations to exercise. The extent to which PFAS influence these signaling pathways remains unknown. The limited evidence available from animal studies suggests that PFAS may adversely affect the metabolic potential of skeletal muscle. Given the widespread presence of PFAS in the environment and their accumulation within the human body, the research proposed in this project has substantial societal and public health relevance.
Scientific evidence indicates that PFAS bioaccumulate in critical organs, including the liver, kidneys, and placenta, potentially affecting fetal development and long-term metabolic health. PFAS have been detected in multiple tissues and are characterized by prolonged biological half-lives ranging from several months to as long as six years. PFAS are known to disrupt lipid metabolism and vascular function, potentially contributing to the development of metabolic syndrome and type 2 diabetes mellitus. They have also been identified as compounds capable of altering lipid storage and energy metabolism, thereby promoting obesity. Available evidence further suggests that PFAS exposure is associated with an increased risk of cardiovascular diseases, including hypertension, atherosclerosis, and heart failure. These adverse health effects may be amplified in urban populations exposed to high levels of environmental pollution and characterized by sedentary lifestyles with limited physical activity. Consequently, both elevated PFAS exposure and physical inactivity may independently and synergistically contribute to the burden of chronic diseases.
Given the well-established anti-inflammatory effects of physical activity and its recognized role as a non-pharmacological strategy for health promotion and rehabilitation, it is essential to determine whether PFAS accumulation limits exercise-induced adaptations and impairs the endocrine function of skeletal muscle. Recent studies suggest that environmental pollutants may influence exercise responses and PFAS clearance dynamics. However, the mechanisms regulating exercise-induced PFAS redistribution remain largely unknown. A limited number of animal studies have demonstrated potential adverse effects of PFAS on skeletal muscle cells and their regenerative capacity, whereas comparable human studies are lacking.
In recent years, myokines and exerkines have emerged as key mediators of health-promoting adaptations to exercise. Nevertheless, little is known about how persistent environmental pollutants modulate their secretion and biological activity. In our previous studies, we observed substantial interindividual variability in exercise-induced responses of several key myokines and exerkines, including interleukin-6 (IL-6), soluble IL-6 receptor, gp130, irisin, decorin, follistatin, myostatin, IL-15, N-lactoyl-phenylalanine (Lac-Phe), and brain-derived neurotrophic factor (BDNF). Given the ubiquitous presence of PFAS and their potential impact on public health, further research is urgently needed to elucidate the mechanisms of PFAS bioaccumulation, elimination, and potential mitigation strategies.
According to national cancer statistics from 2022, breast cancer accounted for 23.6% of all female cancer cases in Poland (N = 21,554; ASW = 60.6; ESP2013 = 103.9). In the Greater Poland region, the corresponding figure was 25.5% (N = 2,221; ASW = 71.8; ESP2013 = 122.2). Despite substantial improvements in oncological treatment outcomes, women diagnosed with estrogen receptor-positive (ER+) breast cancer, which represents the majority of cases, typically receive adjuvant endocrine therapy with aromatase inhibitors (AIs) for a period of 5-10 years. Although such treatment significantly improves survival, it is associated with numerous adverse effects, leading 20-50% of patients to discontinue therapy prematurely. These treatment-related consequences often result in hypokinesia and fear of physical activity, thereby promoting the development of sarcopenia and osteopenia. Disturbances in glucose homeostasis, overweight and obesity, and impaired cardiovascular and respiratory function are also frequently observed. Recent epidemiological findings published in 2025, based on data from the UK Biobank (n = 315,457 participants, including 48.1% women; mean age 56.1 ± 8.2 years) and more than 10 years of follow-up, demonstrated that failure to meet World Health Organization (WHO) recommendations for waist circumference was associated with an 11% increase in overall cancer risk, whereas failure to meet WHO physical activity recommendations was associated with a 5% increase in cancer risk. From a preventive medicine perspective, it is difficult to establish a hierarchy among the numerous factors influencing women's health. Importantly, not only body composition but also optimal cardiovascular and cardiac function appear to be central determinants of health outcomes. It may be hypothesized that hypokinesia, overweight, obesity, low muscle and bone mass, reduced concentrations of myokines, hormonal alterations, and cancer collectively impair cardiovascular function. Although numerous studies have demonstrated the beneficial effects of physical activity on health, a key unanswered question is whether physical activity influences PFAS distribution within the human body and facilitates their elimination. While considerable attention has been devoted to chronic PFAS exposure and the long-term consequences of accumulation, relatively little is known about the effects of acute physiological stressors, such as high-intensity exercise, on PFAS distribution within the circulation. Therefore, the development of evidence-based exercise programs and the identification of previously unrecognized factors regulating adaptive responses are of considerable importance for women's health. Collectively, the available evidence strongly supports the need for further research and preventive actions in this area.
The project will address the following research questions:
- To determine and compare baseline concentrations of PFAS and selected myokines/exerkines (proteins released in response to skeletal muscle contraction) in women entering the study. Which factors determine cardiorespiratory fitness, cardiovascular function, and the capacity for PFAS redistribution and elimination from the body?
- To determine changes in circulating concentrations of selected myokines/exerkines in relation to PFAS concentrations following two supervised 6-month exercise interventions. Does exercise intensity and regularity influence PFAS redistribution and elimination, thereby improving women's health outcomes? Which exercise program is more effective in promoting PFAS elimination from the body?
- To determine the role of physical activity in PFAS redistribution and elimination. The findings may provide an additional rationale for promoting long-term engagement in regular physical activity among women. For this reason, participants will undergo a further assessment six months after completion of the intervention. PFAS concentrations will be assessed in both blood and urine and correlated with changes in exercise-induced proteins.
- To develop and validate a method for PFAS determination in urine samples in order to characterize patterns of PFAS redistribution and elimination.
To determine whether previous cancer treatment combined with aromatase inhibitor therapy affects the endocrine potential of skeletal muscle in physically active women, and whether PFAS burden attenuates the regenerative capacity of skeletal muscle.
Milestone I The results obtained during the first stage of the project will allow to determine how PFAS concentrations, lifestyle factors, health literacy, dietary habits, and physical activity influence the endocrine function of skeletal muscle, circulating concentrations of myokines/exerkines, arginine metabolites, and overall health status in participating women.
The collected data and subsequent analyses will provide insights into the concept of the "endocrine potential" of skeletal muscle. Traditionally, body composition and health status have often been assessed using body mass index (BMI) alone. However, increasing evidence highlights the importance of skeletal muscle not only as a locomotor and stabilizing tissue but also as a key endocrine organ.
The application of advanced methods for assessing circulating myokines/exerkines and PFAS concentrations will enable a more precise characterization of skeletal muscle function and the role of health-related behaviors. The interdisciplinary nature of the proposed research, focusing on the relationship between PFAS exposure and skeletal muscle endocrine function-an area not previously investigated-constitutes the innovative aspect of the project.
Milestone II The objective of this stage is to determine how previous cancer treatment in women who have undergone breast cancer therapy affects the endocrine potential of skeletal muscle. Thee investigators will also establish whether cancer treatment is associated with increased PFAS concentrations as a consequence of impaired skeletal muscle endocrine function.
Milestone III To identify the most effective form of physical activity for promoting PFAS redistribution and elimination from the body. Following the six-month intervention period, implementation of the exercise programs, and completion of the planned biochemical analyses, it will be possible to determine which training modality provides greater health benefits.
The investigators hypothesize that resistance-type exercise will be more effective in facilitating PFAS elimination due to the greater involvement of skeletal muscle mass and consequently how that both exercise interventions will improve cardiovascular function and cardiorespiratory fitness.
Milestone IV To evaluate whether maintaining a daily physical activity level of approximately 8,000 steps is sufficient to promote PFAS elimination in women who have completed cancer treatment and are receiving aromatase inhibitor therapy.
In addition, the impact of PFAS and myokines/exerkines concentrations on the immune potential of CD8⁺ T cells and CD3⁺ T cells will be assess.
Milestone V To develop evidence-based recommendations regarding PFAS redistribution and elimination in women, with particular emphasis on breast cancer survivors.
The final outcome of this stage will be the determination of how the implemented exercise interventions improve cardiovascular function through alterations in arginine metabolite profiles, improvements in exercise-test parameters, and modulation of the endocrine function of skeletal muscle.
Milestone VI Dissemination of the developed recommendations in the form of practical guidelines entitled: "Myths and Facts of the Two-Way Path to Health: Muscles and the Environment."
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Marzena Szerment, MA
- Numero di telefono: 0048618355061
- Email: marzena.szerment@awf.poznan.pl
Backup dei contatti dello studio
- Nome: Ewa Ziemann, Professor
- Numero di telefono: 0048606330944
- Email: ewa.ziemann@awf.poznan.pl
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria (HICT, IWT and Control groups):
- Women,
- aged 35-75 years
- qualified by a physician for participation in the study and with no contraindications to the training intervention (e.g., heart failure, asthma, chronic obstructive pulmonary disease [COPD], or arthritis)
Inclusion Criteria (Onco Group):
- Women ,
- aged 35-75 years,
- Diagnosed with invasive breast cancer, Stage I-III disease according to the TNM classification,
- Estrogen receptor-positive (ER+) breast cancer, defined as expression in at least 10% of tumor cell nuclei,
- Adjuvant hormone therapy with an aromatase inhibitor for at least 6 months,
- BMI between 18.5 and 32 kg/m².
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- No chronic diseases limiting the possibility of oncological treatment.
- No contraindications to daily physical activity.
- Willingness to maintain a daily step count of 8,000 steps.
Exclusion Criteria (HICT, IWT and Control groups):
- history of cardiovascular disease,
- previous hospitalization for cardiovascular conditions,
- ongoing cardiovascular treatment, or recent cardiovascular symptoms,
- advanced osteoporosis
Exclusion Criteria (Onco Group):
- Stage IV invasive breast cancer according to the TNM classification.
- ECOG performance status ≥2.
- Unstable ischemic heart disease.
- Cardiac arrhythmias.
- Advanced degenerative joint disease.
- Rheumatic disorders (including rheumatoid arthritis, osteoarthritis, or fibromyalgia).
- Progression of chronic diseases.
- Pregnancy.
- BMI <18.5 or >32 kg/m².
- Uncontrolled hypothyroidism or hyperthyroidism.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Control Group
The healthy, control group (n = 70) will be included in the study.
Assessments will be conducted at three time points.
Participants will be instructed not to modify their usual lifestyle throughout the study period.
|
|
|
Sperimentale: IWT- Interval Walking Training
The healthy IWT group- a six-month supervised exercise intervention conducted under the supervision of a qualified exercise trainer.
|
Interval Walking Training will consist of five repetitions of alternating 3-minute intervals of fast and slow walking, resulting in a total exercise duration of 30 minutes per session.
The training period will last 6 months, two training session/a week.
|
|
Sperimentale: HICT-High Intensity Circuit Training
The healthy HICT group - a six-month supervised exercise intervention conducted under the supervision of a qualified exercise trainer.
|
HICT training will consist of ten exercises: jumping jacks, push-ups, abdominal crunches, squats, planks, triceps dips using a chair, high knees (running in place), lunges, push-ups with rotation, and side planks.
Each exercise will be performed for 30 seconds, followed by a 10-second transition period.
A 2-minute rest period will be provided between sets.
Training period will last 6 monts /a two training session a week
|
|
Sperimentale: Onco-female group
A group of female cancer survivors will be included in the study.
Participants will be encouraged to achieve a moderate level of physical activity equivalent to approximately 8,000 steps per day.
Physical activity will be continuously monitored using wearable step-counting devices, and compliance with the prescribed activity will be regularly supervised by a physiotherapist.
|
Walking training is addressed to breast cancer patients who have already finished onco-treatment.
Participants will be instructed to maintain a daily step count of 7,000-10,000 steps throughout the study period.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Blood Cell Counts (×10⁹/L)
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Blood Cell Counts (×10⁹/L): White Blood Cell Count (WBC), Platelet Count (PLT), Neutrophil Count (NEUT), Lymphocyte Count (LYMPH), Monocyte Count (MONO), Eosinophil Count (EOS), and Basophil Count (BASO) will be determined using standard analytical method.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Leukocyte Differential Percentages (%)
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
The percentages (%) of neutrophils (NEUT), lymphocytes (LYMPH), monocytes (MONO), eosinophils (EOS), and basophils (BASO) will be determined as part of the complete blood count with differential.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Red Blood Cell Count (RBC)
Lasso di tempo: At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Red Blood Cell Count (×10¹²/L)
|
At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Blood Concentrations
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Blood Concentrations (g/dL): Hemoglobin Concentration (HGB) and Mean Corpuscular Hemoglobin Concentration (MCHC).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Hematological Volume Indices
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Hematological Volume Indices (fL): Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Mean Hemoglobin Content
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Mean Hemoglobin Content (pg): Mean Corpuscular Hemoglobin (MCH).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Hematological Percentage Indices
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Hematological Percentage Indices (%): Hematocrit (HCT), Red Cell Distribution Width (RDW), Platelet Distribution Width (PDW), Plateletcrit (PCT), and Platelet Large Cell Ratio (P-LCR) .
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Irisin, BDNF, IL-6, gp130, sIL-6R, IL-15, IL-15Rα, decorin, myostatin, follistatin, MuRF1, and Lac-Phe
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Selected myokines and exerkines, including irisin, brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), gp130, soluble IL-6 receptor (sIL-6R), IL-15, IL-15Rα, decorin, insulin, myostatin, follistatin, muscle RING-finger protein-1 (MuRF1; an E3 ubiquitin ligase commonly used as a marker of muscle atrophy), and N-lactoyl-phenylalanine (Lac-Phe), will be quantified using enzyme-linked immunosorbent assays (ELISA) with commercially available high-sensitivity kits from reputable manufacturers.
Blood serum or plasma will be used (as per requirements).
All proteins will be expressed in ng/ml.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
T-Lymphocyte Subpopulation Percentages (%)
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
The percentage (%) of CD4⁺CCR7⁺, CD8⁺CCR7⁺, CD4⁺CD28⁺, and CD8⁺CD28⁺ cell populations will be determined by flow cytometry.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
L-arginine, L-citrulline, L-ornithine, ADMA, SDMA
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Arginine metabolites will be quantified in serum using the isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) technique, which has been successfully applied in our previous studies.
All metabolites will be expressed in ng/ml.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Per- and Polyfluoroalkyl Substances (PFAS)
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
PFAS concentrations in plasma and urine samples will be quantified using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS).
A panel of 18 PFAS, among the most commonly detected and widely used, has been selected for analysis.
All PFAS will be expressed in ng/ml.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Inflammatory ratio
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Inflammatory hematological ratios Indicators of inflammation (Neutrophil to Lymphocyte ratio, Monocyte to Lymphocyte ratio, Platelet to Lymphocyte ratio) will be calculated made based on hematological medical records.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
HOMA-%B, HOMA-%S,
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Indices of insulin resistance and insulin sensitivity, including pancreatic β-cell function (HOMA-%B), insulin sensitivity (HOMA-%S) will be calculated.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Blood glucose
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Blood glucose concentration (mg/dl) will be measured using standard analytical methods.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Glycated hemoglobin
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Glycated hemoglobin (HbA1c) (%) will be measured using standard analytical methods.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Insulin
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Serum insulin ( µIU/ml ) concentration will be measured using a high-sensitivity immunoenzymatically assay according to the manufacturer's instructions.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Insulin resistance
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Insulin resistance (HOMA-IR) will be calculated.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Oxygen uptake at rest, at anaerobic threshold and maximal intensity
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Oxygen uptake will be measured and expressed in absolute VO₂ L·min-¹ values
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Oxygen uptake at rest, at anaerobic threshold and maximal intensity
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Description: Oxygen uptake will be measured and expressed in relative VO₂ mL·min-¹ kg-¹ values.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Heart Rate
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Resting and maximal Heart Rate (beats/min).
This outcome will be measured during the Ramp test.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Body Height
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Body Height (m) is measured using Digital stadiometer (Seca 285, SECA, Hamburg, Germany).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Total body mass, Total fat mass, Total lean mass, Android fat mass, Gynoid fat mass, Intra-Cellular Water, Extra-Cellular Water, Total Body Water, Bone Mass component
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Body compositions (kg) including body weight, fat tissue, muscle mass, bone density will be tested by the dual X-ray absorptiometry method (DXA, Lunar Prodigy; General Electric Lunar Healthcare Technologies, Madison, USA and enCORE v. 16 SP1 software).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Bone Mineral Density
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Bone Mineral Density (g/cm2).
Indicator of bone mineral density will be tested by the dual X-ray absorptiometry method (DXA, Lunar Prodigy; General Electric Lunar Healthcare Technologies, Madison, USA and enCORE v. 16 SP1 software).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Percent body fat
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Percentage of fat mass (%) will be assessed using dual X-ray absorptiometry (DXA, Lunar Prodigy; General Electric Lunar Healthcare Technologies, Madison, USA, and enCORE v. 16 SP1 software).
It will be expressed as a percentage of total body mass.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Visceral Adipose Tissue
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Visceral Adipose Tissue (cm3).
It will be tested by the dual X-ray absorptiometry method (DXA, Lunar Prodigy; General Electric Lunar Healthcare Technologies, Madison, USA and enCORE v. 16 SP1 software).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Relative Skeletal Muscle Mass Index
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Relative Skeletal Muscle Mass Index (RSMI) (kg/m2).
Indicators of body composition will be tested by the dual X-ray absorptiometry method (DXA, Lunar Prodigy; General Electric Lunar Healthcare Technologies, Madison, USA and enCORE v. 16 SP1 software).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Handgrip strength - HGS
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
HGS will be measured using a calibrated handheld dynamometer.
Participants will perform maximal voluntary contractions with the dominant hand, and the highest value obtained from three attempts will be recorded for analysis.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Quality of life - Functional scores (body image, sexual functioning, sexual enjoyment, future perspective)
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Quality of life - Functional scores (body image, sexual functioning, sexual enjoyment, future perspective) assessment with EORTC QLQ-BR23 Questionnaire (Breast cancer module).
On the scale minimum value is 1, maximum value is 4. A high score represents a high /healthy level of functioning (better outcome).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Quality of life - Symptom scores (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss)
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Quality of life - Symptom scores (systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss) assessment with EORTC QLQ-BR23 Questionnaire (Breast cancer module).On the scale minimum value is 1, maximum value is 4. A high score for a symptom scale represents a high level of symptomatology / problems (worse outcome).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Level of Physical Activity
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
A self-report scale that measures physical activity.
The IPAQ comprises 27 items that assess time spent engaging in various levels of physical activity and includes sitting time.
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Health literacy
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Health literacy will be evaluated using a validated 47-item questionnaire, designed to assess an individual's ability to access health information, understand such information, evaluate its reliability, and apply it in everyday decision-making. The questionnaire covers three key domains: healthcare (HC-HL), disease prevention (DP-HL), and health promotion (HP-HL). Mean scores are calculated separately for each domain. Scores range from 1 to 4, and from 1 to 5. Higher scores indicate greater health literacy strengths within the respective domain. No overall total HLQ score will be calculated. |
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
|
Dietary habits
Lasso di tempo: "At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Dietary intake will be evaluated based on a 3-day food record, including two weekdays and one non-working day (weekend day).
|
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Socio-demographic characteristics
Lasso di tempo: On day 1
|
Socio-demographic characteristics are collected with study-specific questionnaires.
|
On day 1
|
|
Clinical history
Lasso di tempo: On day 1
|
Only for Onco-group clinical history will be collected with study-specific questionnaires and medical records.
|
On day 1
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Urszula Czerniak, PhD, Poznan University of Physical Education
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NdRS/SP/0034/2025/01 (Altro numero di sovvenzione/finanziamento: Ministry of Science and Higher Education in Poland)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Experimental: IWT- Interval Walking Training
-
Rigshospitalet, DenmarkCompletatoDiabete mellito, tipo 2Danimarca
-
University of Kansas Medical CenterReclutamentoArtrosi, ginocchioStati Uniti
-
Institut d'Investigació Biomèdica de Girona Dr....Attivo, non reclutanteRiabilitazione | Infezione respiratoria da COVID-19 | FisioterapistiSpagna
-
Umeå UniversityRegion VästerbottenReclutamento
-
University of MinnesotaRitiratoSchizofrenia | Disturbo schizoaffettivo | PsicosiStati Uniti
-
Kuopio Research Institute of Exercise MedicineKuopio University Hospital; University of Basel; University of Eastern Finland; Social...TerminatoAngina pectoris instabile | Infarto miocardico acuto | Infarto miocardico ricorrenteFinlandia
-
University Hospitals Coventry and Warwickshire...University of Hull; Wake Forest University Health Sciences; University of Warwick; Bangor University e altri collaboratoriCompletatoMalattia coronaricaRegno Unito
-
California State University, San MarcosCompletatoMiglioramento del VO2max e della gittata cardiaca in risposta all'allenamentoStati Uniti
-
Chang Gung Memorial HospitalCompletatoFibrosi miocardica
-
Rigshospitalet, DenmarkReclutamentoBroncopneumopatia cronica ostruttivaDanimarca